« Pfizer and Merck Take Opposite Tack on R&D vs EPS | Main | Delbiopharm Partners on RNAi with Marina Biotech »



TrackBack URL for this entry:

Listed below are links to weblogs that reference In the Pipeline looks at Pfizer/Merck R&D Forked Paths Taken:


Feed You can follow this conversation by subscribing to the comment feed for this post.

Sabine Mildor


there is a good link collection here:


Best regards,


Mike Wokasch

The challenges facing large, mega-merged pharma companies like Pfizer and Merck are well documented in the book Pharmaplasia™. These companies have few short term growth options left (e.g., buy another company).

For long-term growth they can either downsize operations (not R & D) to a point where they once again innovate with an intense focus on discovery research or they can build a “big box” model with a core competency for acquiring and commercializing broad product offerings in the evolving new healthcare market. I believe the R & D focused companies will prevail, because without innovative new products, there is no "big box" option. www.pharmareform.com

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

July 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31    

Innovate on Purpose

In the Pipeline

Life Sci VC

visited 6 states (46.1%)
Create your own visited map of Canada